Gilead Sciences (NASDAQ:GILD) Price Target Cut to $168.00 by Analysts at Morgan Stanley

Gilead Sciences (NASDAQ:GILD) had its price objective cut by Morgan Stanley from $175.00 to $168.00 in a report issued on Friday morning,MarketScreener reports.

Other analysts have also issued research reports about the company. Royal Bank Of Canada cut their price objective on Gilead Sciences from $123.00 to $122.00 and set a “sector perform” rating for the company in a report on Friday. Citigroup upped their price target on Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a research report on Monday, April 13th. Jefferies Financial Group initiated coverage on Gilead Sciences in a research note on Tuesday, March 10th. They issued a “buy” rating and a $180.00 price target for the company. Wolfe Research boosted their price target on Gilead Sciences from $155.00 to $170.00 and gave the company an “outperform” rating in a research note on Thursday, February 12th. Finally, Rothschild & Co Redburn increased their price objective on Gilead Sciences from $159.00 to $170.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $157.15.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $131.33 on Friday. The company has a market capitalization of $163.01 billion, a price-to-earnings ratio of 17.89, a price-to-earnings-growth ratio of 1.77 and a beta of 0.31. The business has a 50 day simple moving average of $139.59 and a 200-day simple moving average of $132.87. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98. Gilead Sciences has a twelve month low of $96.18 and a twelve month high of $157.29.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a return on equity of 49.45% and a net margin of 30.99%.The company had revenue of $6.96 billion during the quarter, compared to analyst estimates of $6.91 billion. During the same quarter in the previous year, the firm posted $1.81 EPS. The firm’s quarterly revenue was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, equities research analysts expect that Gilead Sciences will post 8.62 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be given a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 2.5%. The ex-dividend date is Monday, June 15th. Gilead Sciences’s dividend payout ratio (DPR) is 48.45%.

Insider Activity at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction on Tuesday, April 28th. The stock was sold at an average price of $129.16, for a total value of $1,291,600.00. Following the transaction, the chief executive officer directly owned 632,567 shares in the company, valued at $81,702,353.72. This trade represents a 1.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $140.96, for a total value of $422,880.00. Following the transaction, the chief financial officer owned 176,191 shares in the company, valued at approximately $24,835,883.36. This represents a 1.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 63,000 shares of company stock valued at $9,238,250 in the last three months. Corporate insiders own 0.30% of the company’s stock.

Institutional Trading of Gilead Sciences

A number of institutional investors have recently modified their holdings of the company. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at about $25,000. Vermillion & White Wealth Management Group LLC increased its position in shares of Gilead Sciences by 71.4% in the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 85 shares during the last quarter. Corundum Trust Company INC acquired a new stake in shares of Gilead Sciences in the third quarter valued at about $26,000. Quattro Advisors LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at about $26,000. Finally, Wealth Preservation Advisors LLC increased its position in shares of Gilead Sciences by 60.0% in the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 81 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Truist Financial reaffirmed its buy rating on Gilead and raised its price target to $157 from $155, implying meaningful upside from current levels. Benzinga
• Positive Sentiment: Gilead reported Q1 EPS of $2.03 and revenue of $6.96 billion, both ahead of analyst expectations, supported by HIV and Trodelvy sales growth. Yahoo Finance
• Positive Sentiment: The company raised its Yeztugo 2026 sales guidance to $1 billion from $800 million, signaling stronger-than-expected launch momentum. Yahoo Finance
• Neutral Sentiment: RBC slightly reduced its price target to $122 from $123 and kept a sector perform view, suggesting a more cautious stance but no major change in thesis. Benzinga
• Negative Sentiment: Gilead cut its 2026 EPS guidance to a loss range of -$1.05 to -$0.65, a major deterioration from prior profit expectations, due to acquisition charges and financing costs. Reuters
• Negative Sentiment: Investors also appear concerned that near-term growth is being driven more by older products like Descovy and Biktarvy than by the much-anticipated Yeztugo launch, creating questions about the pace of future growth. Yahoo Finance

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.